Pharmaceuticals News and Research

RSS

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of multiple Dupuytren's contracture cords concurrently.

20 Dec 2013

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties - an effect for which these pharmaceutical agents are not usually tested.

20 Dec 2013

Coupling meditation-like practices with drug and behavior therapies more helpful in tackling addiction

Using a computational model of addiction, a literature review and an in silico experiment, theoretical computer scientist Yariv Levy and colleagues suggest in a new paper this week that rehabilitation strategies coupling meditation-like practices with drug and behavior therapies are more helpful than drug-plus-talk therapy alone when helping people overcome addiction.

20 Dec 2013

Submicrometer line focusing reduces protein crystal damage, enhances drug development

New recommendations for using X-rays promise to speed investigations aimed at understanding the structure and function of biologically important proteins - information critical to the development of new drugs.

20 Dec 2013

ORIX USA Health partners with TGen and TD2 to support Arizona's biomedical economy

ORIX USA Health and Life Sciences has completed an investment into Translational Drug Development (TD2) through the purchase of equity from the Translational Genomics Research Institute (TGen).

20 Dec 2013

Study reveals that global pricing teams outsource 50% of activities

On average, global pricing teams outsource 50% of activities that they budget for, according to study of pharmaceutical pricing teams by Cutting Edge Information.

20 Dec 2013

PeptiDream signs Collaboration and License Agreement with Lilly

PeptiDream Inc, a Tokyo-based biopharmaceutical company, announced that they have entered into a Collaboration and License Agreement with US-based Eli Lilly and Company on 19 December 2013.

20 Dec 2013

MicuRx announces initiation of global clinical development program for MRX-I compound

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the initiation of a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

Nuvo Research, NovaMedica enter into agreement to market Pennsaid products in Russia

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology, and NovaMedica LLC, a Russian pharmaceutical company, today announced that they have signed a supply and distribution agreement providing NovaMedica the exclusive rights to market and sell Nuvo's Pennsaid 1.5% and Pennsaid 2% products in Russia and some of the Community of Independent States.

19 Dec 2013

PM360 names Atlantis Healthcare as Innovator in Pharma Marketing

Atlantis Healthcare, a global leader in treatment adherence programs, was named an Innovator in Pharma Marketing by PM360 in their special 2013 Innovators issue. The annual showcase honors 60 of the "most forward-thinking ideas and problem solving solutions" that meet current needs in pharmaceutical marketing.

19 Dec 2013

Collaborative pharmaceutical project focusing on paediatric formulation development gets go-ahead

A collaborative pharmaceutical project focused on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an innovation grant.

19 Dec 2013

Merck and CNIO sign agreement to collaborate in area of cancer drug development

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development.

19 Dec 2013

Bristol-Myers Squibb signs agreement to sell global diabetes business

Bristol-Myers Squibb Company today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.

19 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

KIT researchers develop novel gel for biological and medical applications

A novel method developed by researchers from Karlsruhe Institute of Technology (KIT) and Jacobs University Bremen enables manufacturing of polymer layers with tailor-made properties and multiple functions: A stable porous gel (SURGEL) for biological and medical applications is obtained from a metal-organic framework (SURMOF) grown up on a substrate.

19 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Merck signs license agreement with CNIO for cancer drug development

Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

18 Dec 2013

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Pharmaceuticals News and Research

Auxilium seeks FDA approval for XIAFLEX sBLA to treat multiple Dupuytren's contracture cords concurrently

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Coupling meditation-like practices with drug and behavior therapies more helpful in tackling addiction

Submicrometer line focusing reduces protein crystal damage, enhances drug development

ORIX USA Health partners with TGen and TD2 to support Arizona's biomedical economy

Study reveals that global pricing teams outsource 50% of activities

PeptiDream signs Collaboration and License Agreement with Lilly

MicuRx announces initiation of global clinical development program for MRX-I compound

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Nuvo Research, NovaMedica enter into agreement to market Pennsaid products in Russia

PM360 names Atlantis Healthcare as Innovator in Pharma Marketing

Collaborative pharmaceutical project focusing on paediatric formulation development gets go-ahead

Merck and CNIO sign agreement to collaborate in area of cancer drug development

Bristol-Myers Squibb signs agreement to sell global diabetes business

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

KIT researchers develop novel gel for biological and medical applications

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Merck signs license agreement with CNIO for cancer drug development

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence